This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Pre-hepatic metabolism (bilirubin)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Bilirubin is first formed in macrophages of the reticuloendothelial system. The initial substrate is predominantly haemoglobin, but any compound containing a haem nucleus may be a precursor e.g. catalase, myoglobin.

The source of haemoglobin is senescent erythrocytes. They are phagocytosed by the macrophage. 7.5g per day of haemoglobin are released in the healthy adult.

Within the macrophage, haemoglobin is broken down to:

  • globin chains; broken down into constituent amino acids for recycling
  • haem group

Then, the haem group is cleaved by the enzyme haem oxygenase to liberate:

  • iron cations; stored in macrophage and recycled to cytoplasmic pool
  • carbon monoxide; expired via lungs
  • biliverdin

Biliverdin is converted to bilirubin by the enzyme biliverdin reductase. Up to 250mg of bilirubin is produced per day in the healthy adult.

Bilirubin is insoluble in water and so must be carried by albumin within plasma. Binding with albumin also shields it from uptake by adipose tissue with subsequently reduced toxicity. Bilirubin then circulates haematogenously before uptake by the liver.

If not taken up by the liver or if produced in excess, unconjugated bilirubin is deposited in extra-hepatic tissues. This results in pre-hepatic jaundice.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.